News

Researchers at Università degli Studi di Milano in Italy recently published in the journal Cells a review regarding the link between autophagy and amyotrophic lateral sclerosis (ALS). The study is entitled “Autophagy and Neurodegeneration: Insights from a Cultured Cell Model of ALS”. Autophagy…

Researchers at the University of Toronto and the Sunnybrook Health Sciences Centre in Canada recently reported the development of two new antibodies against a protein that plays a key role in amyotrophic lateral sclerosis (ALS) – C9ORF72. The study was published in the journal Annals…

A new research collaboration was recently formed between Biogen Idec, the ALS Association and Columbia University Medical Center (CUMC) to study the differences and similarities in ALS’ disease progress and how an patient’s genes can influence its clinical manifestations. The joint research initiative, titled, “Genomic Translation for ALS Clinical care” (GTAC), will entail…

Presymptomatic patients suffering with amyotrophic lateral sclerosis (ALS) ingest more calories per day but have lower body-mass index (BMI) in comparison to those without ALS. These are the results of a study from researchers in the Netherlands, published by the JAMA Neurology journal, which also assessed ALS disease risk and its connections…

In a recent study entitled “ALS-Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12 Cells” researchers investigated the role of a mutation associated with ALS type-8 (ALS8)  – P56S-VAPB mutation – on skeletal muscle cells homeostasis and muscle formation. The study was published in the…

People who participated in last year’s Ice Bucket Challenge have helped to make a difference in the lives of ALS patients that live in the area of St. Louis. The ALS Association was able to double their donations, which increased the associations’ support for ALS patient care, education,…

A study led by researchers at the National Institute of Neurological Disorders and Stroke (NINDS) recently published in the journal Neuron revealed new insights into why mutations in the SOD1 gene lead to the development of amyotrophic lateral sclerosis (ALS). The study is entitled “…

The ALS Therapy Development Institute has just signed a research partnership with Chaperone Therapeutics, Inc., a company that specializes in treatments that address protein misfolding and neuronal cell loss, the underlying causes of neurodegenerative disease. The new partners will be working on potential treatments for amyotrophic lateral sclerosis (ALS), in order to facilitate preclinical development…